Equities research analysts predict that Scpharmaceuticals Inc (NASDAQ:SCPH) will announce earnings of ($0.48) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Scpharmaceuticals’ earnings. The lowest EPS estimate is ($0.55) and the highest is ($0.36). Scpharmaceuticals reported earnings per share of ($0.27) in the same quarter last year, which suggests a negative year-over-year growth rate of 77.8%. The business is expected to announce its next quarterly earnings report on Thursday, March 19th.
On average, analysts expect that Scpharmaceuticals will report full year earnings of ($1.66) per share for the current year, with EPS estimates ranging from ($1.72) to ($1.55). For the next financial year, analysts anticipate that the firm will post earnings of ($1.70) per share, with EPS estimates ranging from ($2.15) to ($1.02). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Scpharmaceuticals.
Scpharmaceuticals (NASDAQ:SCPH) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.33) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.12.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Eversept Partners LP bought a new position in Scpharmaceuticals during the 2nd quarter valued at $556,000. Alambic Investment Management L.P. bought a new position in Scpharmaceuticals during the 2nd quarter valued at $191,000. Jacobs Levy Equity Management Inc. boosted its stake in Scpharmaceuticals by 55.8% during the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 36,921 shares of the company’s stock valued at $118,000 after acquiring an additional 13,225 shares during the last quarter. Paloma Partners Management Co bought a new position in Scpharmaceuticals during the 2nd quarter valued at $96,000. Finally, Matisse Capital bought a new position in Scpharmaceuticals during the 3rd quarter valued at $86,000. Hedge funds and other institutional investors own 40.67% of the company’s stock.
SCPH traded down $0.07 during trading hours on Friday, reaching $4.31. 19,549 shares of the stock traded hands, compared to its average volume of 55,291. The firm’s fifty day simple moving average is $5.04 and its two-hundred day simple moving average is $5.00. The company has a market cap of $80.31 million, a price-to-earnings ratio of -2.71 and a beta of 0.67. Scpharmaceuticals has a fifty-two week low of $2.44 and a fifty-two week high of $7.85. The company has a debt-to-equity ratio of 0.34, a current ratio of 10.48 and a quick ratio of 10.47.
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.
See Also: What does a market perform rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.